Sénescence cellulaire réplicative

Animal cells undergo replicative cell senescence, a permanent cell cycle arrest triggered by telomere shortening. As cells divide, telomeres—repetitive DNA sequences at chromosome ends—shorten by 25-200 bases per division. When telomeres become critically short, the protective T-loop structure destabilizes, exposing chromosome ends. This triggers a DNA damage response that halts cell division, preventing genomic instability and cancer development.

Telomeres are repetitive DNA sequences and protein complexes at chromosome ends that act as protective caps. Without telomeres, chromosome ends would be recognized as double-strand breaks and could fuse abnormally into ring chromosomes. The shelterin protein complex maintains a T-loop structure that masks DNA ends, preventing degradation by nucleases and aberrant fusion between chromosome ends.

As telomeres shorten with each cell division, shelterin components are displaced from the telomere region. This destabilizes the T-loop structure, leaving chromosome ends exposed. The exposed ends are sensed as DNA damage by the DNA damage response pathway, which induces persistent signaling that triggers replicative cell senescence and permanent cell cycle arrest.

Telomerase is an enzyme that adds telomeric repeat sequences, enabling repetitive cell division. Embryonic stem cells express active telomerase, but in adults, telomerase is active only in cells requiring regular division. Most human somatic cells lack telomerase activity, causing telomere length to decrease with every cell division, eventually triggering replicative cell senescence.

Replicative cell senescence limits the replicative capacity of cells, suppressing abnormal proliferation and tumor formation. By restricting the number of divisions, cells cannot accumulate the mutations necessary for malignant transformation. However, rare mutations that reactivate telomerase can reconstruct telomeres, allowing abnormal proliferation. This makes telomerase an ideal target for anticancer therapy, as most cancer cells express telomerase while normal cells do not.

Oncogenic mice studies provide experimental proof. When oncogenic mice carrying cancer-causing genes were crossed with telomerase-deficient mice, successive generations exhibited progressively shorter telomeres. Late-generation mice with shorter telomeres showed reduced tumor frequency compared to early-generation mice with longer telomeres, proving that limiting replicative capacity suppresses tumor formation.

In mitogenic medium, human fibroblast cells divide approximately 25-50 times before entering replicative cell senescence. As cells approach this finite division limit, the rate of cell division slows and eventually halts completely. This phenomenon, called the Hayflick limit, reflects the progressive shortening of telomeres with each cell cycle.